Metrics as Leverage Points Metrics earn their power to change systems when they are simultaneously measurable, actionable, and meaningful. When a metric achieves that status, it tends to cascade across … Read More
Metrics That Moved Systems (Part 2) Historical Precedents and Implications for the BHE Framework
Purpose This note synthesizes lessons reviewed in Part 1 of this series from six historical cases in which disease metrics drove transformative, system-level change. In Part 2 we draw direct … Read More
Different Measures for Different Roles: BHE and Quality Measurement
Purpose In our two-part series, Metrics that Moved Systems, we examined six historical cases in which disease metrics drove transformative, system-level change and drew direct implications for the design of … Read More
NEWDIGS’ Response to HHS Request for Comment on the Update to the National Plan to Address Alzheimer’s Disease
We’ve submitted formal comment to HHS on its update to the National Plan to Address Alzheimer’s Disease (Docket HHS-ASPE-2026-0298). It’s a response we’ve been building toward for a while — … Read More
Stigma & Bias
KEY TAKEWAYS Stigma and bias around Alzheimer’s disease (AD) strongly shape when and how people seek diagnosis and treatment. These forces delay help-seeking, worsen inequities, and reduce quality of life … Read More
System changes to empower primary care in Alzheimer’s disease detection and care
New consortium-driven publication in Alzheimer’s & Dementia, The Journal of the Alzheimer’s Association Alzheimer’s science is advancing rapidly. We now have disease-modifying therapies that can slow progression in early disease. … Read More
Advancing the Biomedical Health Efficiency (BHE) of Early Alzheimer’s Disease Care
A focused follow-up to the Alzheimer’s Design Lab Why this matters A clear takeaway from the Design Lab is that we lack a shared, decision-ready understanding of the true value … Read More
The APOE Gene and Risks of Alzheimer’s Disease
KEY TAKEAWAYS Three common variants of the APOE gene influence the likelihood of onset of Alzheimer’s disease over the course of a lifetime and influence the likely rate of disease … Read More
Younger-Onset Alzheimer’s Disease
KEY TAKEWAYS Although younger-onset Alzheimer’s disease (AD) is less common, it creates distinct challenges for individuals impacted by it. The causes of younger-onset AD are often unclear with only a … Read More
Medicare Annual Wellness Visit
KEY TAKEWAYS The Medicare Annual Wellness Visit (AWV) is the only Medicare benefit that offers a no-cost cognitive assessment to beneficiaries in Traditional (fee-for-service) Medicare and Medicare Advantage plans. In … Read More